Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options

Author(s): Sangmee Bae, Sara Hurvitz

Journal Name: Current Cancer Therapy Reviews

Volume 11 , Issue 4 , 2015

Become EABM
Become Reviewer


Trastuzumab has been clearly demonstrated to improve overall survival for both early and metastatic HER2 positive breast cancer. However, despite the improved clinical outcomes seen with the addition of HER2 targeted therapy to conventional cytotoxic agents, the response rates remain between 30-55% and the majority of patients with advanced breast cancer experience disease progression within 1 year. In this review article, we provide a summary of the key mechanisms of resistance to trastuzumab, including the truncated form of HER2 (p95HER2), compensatory up-regulation of receptor cross-talk, genetic mutations and aberrancies in molecular pathways that allow tumor cells to evade cell cycle regulations. In recent years, treatment options for patients with trastuzumab-resistant disease have been developed and approved, including lapatinib and T-DM1. Ongoing research is evaluating multiple other therapeutic regimens that include novel HER2- targeting agents for the treatment of resistant disease. We will review these newer therapies as well as the scientific rationale behind treatment regimens that have been studied in patients with trastuzumab-resistant HER2 positive breast cancer.

Keywords: Breast cancer, HER2, lapatinib, neratinib, metastatic, T-DM1, trastuzumab resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [269 - 291]
Pages: 23
DOI: 10.2174/1573394712666151119213606
Price: $65

Article Metrics

PDF: 30
PRC: 2